The inspection was carried out at Eugia Unit-III, a formulation manufacturing facility operated by Eugia Pharma Specialities, a wholly owned subsidiary of Aurobindo Pharma, located in Pashamylaram, Telangana. The USFDA conducted the inspection between 27 January to 6 February 2026.

At the conclusion of the inspection, the regulator had issued 11 observations to the facility. The company has now informed stock exchanges that the US FDA has determined the inspection classification status as OAI.

Aurobindo Pharma is engaged in the manufacturing and marketing of active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services. The company reported a 2% rise in consolidated net profit to Rs 921.26 crore on a 4.4% increase in net sales to Rs 8,751.50 crore in Q4 FY26 over Q4 FY25.

The counter rose 0.56% closed at Rs 1,472.25 on the BSE on Friday.

Powered by Capital Market - Live News